Facial Myotonia: Evaluation and Management
For facial myotonia, initiate mexiletine as first-line pharmacologic therapy, as it demonstrates the strongest evidence for reducing myotonia symptoms with moderate-certainty evidence in both myotonic dystrophy and non-dystrophic myotonia. 1
Initial Evaluation
When evaluating a patient presenting with facial myotonia, you must first determine the underlying myotonic disorder through:
Essential Diagnostic Workup
- Muscle enzymes: CPK, LDH, AST, ALT, aldolase to differentiate myotonic dystrophy (often elevated) from non-dystrophic myotonia (typically normal)
- Genetic testing: Identify specific channelopathies (chloride, sodium channel mutations) versus myotonic dystrophy type 1 or 2
- EMG: Confirm myotonic discharges with characteristic "dive bomber" sound, though this doesn't reliably detect metabolic myopathies 2
- Exclude alternative diagnoses: Thyroid function, electrolytes, vitamin D, metabolic/mitochondrial myopathies 2
Clinical Assessment
Document the specific pattern and severity:
- Eye closure myotonia (eyelid stiffness)
- Jaw muscle involvement (difficulty releasing bite)
- Facial muscle stiffness and delayed relaxation
- Associated symptoms: pain, cramping, functional disability
Treatment Algorithm
First-Line: Mexiletine
Mexiletine is the evidence-based first choice for symptomatic myotonia treatment based on multiple high-quality RCTs 1:
For Non-Dystrophic Myotonia:
- Mexiletine likely reduces myotonia severity (Interactive Voice Response Diary Stiffness score: MD -3.12,95% CI -3.75 to -2.49; moderate-certainty evidence) 1
- Improves quantitative hand grip and electromyographic outcomes 1
- May improve quality of life (SF-36 scores improved by 6.45 points for physical component, 6.78 points for mental component) 1
For Myotonic Dystrophy Type 1:
- Mexiletine likely reduces hand grip relaxation time by 1.37 seconds (moderate-certainty evidence) 1
- No significant quality of life improvement demonstrated in this population 1
Common Adverse Effects (reported in 94 events vs 29 with placebo):
- Gastrointestinal symptoms (most frequent)
- Lethargy
- Headache 1
Second-Line: Lamotrigine
Consider lamotrigine specifically for non-dystrophic myotonia if mexiletine fails or is not tolerated 1:
- Improves relaxation time (hand grip: 2.80 log seconds; eyelid closure: 2.30 log seconds; low-certainty evidence) 1
- Likely improves quality of life (SF-36: MD 5.00 points; moderate-certainty evidence) 1
- Adverse effects include headache, fatigue, and rash (44 events vs 23 with placebo) 1
Alternative Agents with Limited Evidence
Clomipramine and imipramine showed short-term benefit in small studies for myotonic dystrophy, while taurine demonstrated long-term benefit, but evidence quality is insufficient for routine recommendation 3
Other agents (phenytoin, procainamide, nifedipine, diazepam, quinine) were either ineffective or have uncertain evidence 1
Critical Caveats
Not all patients respond to antimyotonic therapy - the RCTs demonstrate variable individual responses, and research into predictors of treatment response is needed 1
Untested agents including acetazolamide, flecainide, ranolazine, and lacosamide may warrant consideration in refractory cases, though they lack RCT evidence 1
Distinguish from facial synkinesis - this is a completely different condition following facial nerve injury requiring botulinum toxin and physical therapy, not antimyotonic drugs 4
Monitoring Response
Track treatment efficacy using:
- Patient-reported symptom severity
- Timed eyelid closure and jaw release
- Functional impact on daily activities
- Quality of life measures (SF-36)
Adjust dosing or switch agents if inadequate response after 4-8 weeks of therapeutic dosing.